This inventor holds 1 USPTO granted patent. Top assignees: Biology Centre as Cr, V.v.i., Institute for Clinical and Experimental Medicine, Institute of Microbiologyh as Cr, V.v.i.. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3 
1 out of 1 
1 out of 1 Years Active: 2016
Title: Miroslav Petricek: Innovator in Anti-Inflammatory Research
Introduction
Miroslav Petricek is a notable inventor based in Prague, Czech Republic. He has made significant contributions to the field of microbiology and biochemistry, particularly through his research on manumycin-type metabolites. His work has the potential to impact the development of anti-inflammatory agents.
Latest Patents
Miroslav Petricek holds a patent for a manumycin-type metabolite called Colabomycin E. This compound inhibits caspase 1 and the creation of interleukins. The strain that produces Colabomycin E is SOK1/5-04, which has been deposited in The Czech Collection of Microorganisms under the number CCM8556. Colabomycin E is structurally similar to the known metabolite colabomycin A, but it features a polyene chain that is two carbons longer. Biological activity assays have shown that Colabomycin E significantly inhibits IL-1β release from THP-1 cells, indicating its potential as an anti-inflammatory agent.
Career Highlights
Throughout his career, Miroslav Petricek has worked at prominent institutions such as the Biology Centre and the Institute of Microbiology, both as part of the Czech Republic's research community. His research has focused on the production and application of novel metabolites, contributing to advancements in medical and biological sciences.
Collaborations
Miroslav has collaborated with notable colleagues, including Katerina Petrickova and Stanislav Pospisil. Their joint efforts have furthered research in the field of microbiology and the development of new therapeutic agents.
Conclusion
Miroslav Petricek's innovative work on Colabomycin E exemplifies the importance of research in developing new anti-inflammatory treatments. His contributions to microbiology and collaboration with fellow researchers highlight the collaborative nature of scientific advancement.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile